erythromycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1048	114-07-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: erythromycin gluceptate erythromycin lactobionate erythromycin stearate erythromycin Erythromycin A erythrocin erythromycin phosphate erythromycin thiocyanate	A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Molecular weight: 733.94 Formula: C37H67NO13 CLOGP: 1.63 LIPINSKI: 2 HAC: 14 HDO: 5 TPSA: 193.91 ALOGS: -3.20 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

erythromycin gluceptate
erythromycin lactobionate
erythromycin stearate
erythromycin
Erythromycin A
erythrocin
erythromycin phosphate
erythromycin thiocyanate

A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Molecular weight: 733.94
Formula: C37H67NO13
CLOGP: 1.63
LIPINSKI: 2
HAC: 14
HDO: 5
TPSA: 193.91
ALOGS: -3.20
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O
2	g	O
1	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	1 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	5 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	90.88 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	35 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.95 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.10 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 24, 1964	FDA	ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4763.12	12.46	2349	23236	308338	63155099
International normalised ratio fluctuation	245.71	12.46	74	25511	2404	63461033
Bloody discharge	187.46	12.46	54	25531	1497	63461940
Lyme disease	137.79	12.46	52	25533	3397	63460040
Abortion spontaneous	111.14	12.46	115	25470	47080	63416357
Seronegative arthritis	110.26	12.46	46	25539	3913	63459524
Exposure during pregnancy	67.60	12.46	175	25410	155372	63308065
Necrosis ischaemic	61.46	12.46	20	25565	840	63462597
Dislocation of vertebra	58.75	12.46	39	25546	8596	63454841
Anaphylactic reaction	56.40	12.46	98	25487	66002	63397435
Faecal volume decreased	49.58	12.46	12	25573	165	63463272
Drug interaction	48.71	12.46	202	25383	228929	63234508
Beta haemolytic streptococcal infection	48.03	12.46	21	25564	2004	63461433
Pneumonia streptococcal	46.95	12.46	20	25565	1791	63461646
Maternal exposure during pregnancy	46.76	12.46	194	25391	219868	63243569
Amniotic cavity infection	46.70	12.46	18	25567	1245	63462192
Vomiting	46.40	12.46	384	25201	559233	62904204
Death	44.75	12.46	51	25534	374330	63089107
Wheezing	41.95	12.46	108	25477	95487	63367950
Completed suicide	41.45	12.46	5	25580	145668	63317769
Spondylitis	40.54	12.46	24	25561	4330	63459107
Pneumococcal infection	38.36	12.46	12	25573	443	63462994
Mass excision	36.88	12.46	11	25574	345	63463092
Umbilical erythema	36.15	12.46	8	25577	72	63463365
Drug intolerance	35.37	12.46	229	25356	308432	63155005
Ototoxicity	35.17	12.46	15	25570	1347	63462090
Pain	33.67	12.46	169	25416	740459	62722978
Wound infection	33.12	12.46	42	25543	21368	63442069
Vertigo positional	32.69	12.46	18	25567	2831	63460606
Spinal fusion surgery	32.56	12.46	23	25562	5605	63457832
Purpura senile	31.92	12.46	11	25574	552	63462885
Stevens-Johnson syndrome	31.03	12.46	44	25541	24906	63438531
Premature baby	31.01	12.46	40	25545	20695	63442742
Caesarean section	30.54	12.46	36	25549	16996	63446441
Infection	29.99	12.46	176	25409	228997	63234440
Adjustment disorder with depressed mood	29.84	12.46	28	25557	10176	63453261
Tarsal tunnel syndrome	27.90	12.46	10	25575	564	63462873
Rash	27.64	12.46	346	25239	560525	62902912
Bronchial obstruction	27.44	12.46	13	25572	1494	63461943
Urticaria	26.16	12.46	134	25451	165668	63297769
Ulcerative keratitis	25.40	12.46	15	25570	2695	63460742
Serum sickness-like reaction	25.22	12.46	9	25576	501	63462936
Drug tolerance decreased	25.03	12.46	33	25552	17440	63445997
Therapeutic product effect incomplete	24.78	12.46	108	25477	124948	63338489
Benign laryngeal neoplasm	24.37	12.46	5	25580	30	63463407
Premature rupture of membranes	23.46	12.46	18	25567	4975	63458462
Breast cancer stage III	22.11	12.46	24	25561	10362	63453075
Oligohydramnios	21.62	12.46	19	25566	6347	63457090
Iron deficiency	21.45	12.46	20	25565	7210	63456227
Lip swelling	21.38	12.46	42	25543	31021	63432416
Monocytosis	20.74	12.46	8	25577	554	63462883
Resorption bone increased	20.21	12.46	10	25575	1264	63462173
Abdominal pain upper	19.96	12.46	147	25438	206297	63257140
Premature delivery	19.71	12.46	40	25545	30241	63433196
Death neonatal	19.58	12.46	9	25576	966	63462471
Vestibular disorder	19.11	12.46	10	25575	1421	63462016
Ergot poisoning	19.10	12.46	5	25580	96	63463341
Grip strength decreased	18.94	12.46	33	25552	22254	63441183
Maternal drugs affecting foetus	18.51	12.46	16	25569	5226	63458211
Corneal neovascularisation	18.37	12.46	5	25580	112	63463325
Pharyngeal oedema	18.26	12.46	25	25560	13696	63449741
Walking aid user	18.14	12.46	22	25563	10695	63452742
Drug ineffective	17.97	12.46	305	25280	1044460	62418977
Alopecia	17.67	12.46	73	25512	337463	63125974
Corneal perforation	17.42	12.46	7	25578	541	63462896
Toxicity to various agents	17.38	12.46	47	25538	247203	63216234
Mucous stools	17.14	12.46	14	25571	4234	63459203
Fall	16.38	12.46	92	25493	392242	63071195
Jarisch-Herxheimer reaction	16.21	12.46	6	25579	371	63463066
Stenotrophomonas infection	15.87	12.46	10	25575	2017	63461420
Infantile haemangioma	15.32	12.46	4	25581	76	63463361
Starvation ketoacidosis	15.03	12.46	4	25581	82	63463355
Type 2 diabetes mellitus	14.88	12.46	58	25527	63810	63399627
Toxic epidermal necrolysis	14.78	12.46	32	25553	25302	63438135
Live birth	14.52	12.46	32	25553	25598	63437839
Acute generalised exanthematous pustulosis	14.43	12.46	20	25565	11079	63452358
Anaemia	14.41	12.46	65	25520	293365	63170072
Prescribed overdose	14.37	12.46	38	25547	34115	63429322
Febrile neutropenia	14.26	12.46	16	25569	118433	63345004
Cardiac arrest neonatal	14.24	12.46	4	25581	101	63463336
Hypotension	14.23	12.46	59	25526	272545	63190892
Anal candidiasis	14.22	12.46	3	25582	21	63463416
Nodule	13.95	12.46	28	25557	20998	63442439
Malignant neoplasm progression	13.75	12.46	8	25577	82113	63381324
Drug abuse	13.74	12.46	6	25579	72512	63390925
Amnesia	13.38	12.46	51	25534	55534	63407903
Dysphoria	13.33	12.46	13	25572	4953	63458484
Haemoglobin decreased	13.22	12.46	24	25561	145461	63317976
Epidermolysis	12.80	12.46	6	25579	673	63462764
Immunosuppressant drug level increased	12.64	12.46	11	25574	3627	63459810
Neutropenia	12.49	12.46	33	25552	174972	63288465

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	485.70	13.99	290	9189	80239	34867213
Toxic epidermal necrolysis	80.87	13.99	58	9421	21588	34925864
Hyphaema	76.85	13.99	20	9459	567	34946885
Drug interaction	61.31	13.99	166	9313	225780	34721672
Product packaging issue	60.76	13.99	17	9462	637	34946815
Premature baby	56.46	13.99	45	9434	19588	34927864
Dystonia	42.66	13.99	30	9449	10815	34936637
Rhabdomyolysis	41.84	13.99	70	9409	68093	34879359
Mixed liver injury	39.32	13.99	18	9461	2855	34944597
Stupor	39.21	13.99	18	9461	2873	34944579
Low birth weight baby	36.14	13.99	24	9455	7881	34939571
Eye pain	34.79	13.99	29	9450	13433	34934019
Coagulation time prolonged	34.24	13.99	13	9466	1289	34946163
Obstruction gastric	33.61	13.99	12	9467	1001	34946451
Acute generalised exanthematous pustulosis	32.02	13.99	21	9458	6755	34940697
Intraocular pressure increased	31.23	13.99	19	9460	5364	34942088
Foetal death	30.73	13.99	8	9471	227	34947225
Deafness bilateral	28.85	13.99	11	9468	1103	34946349
Brain oedema	28.13	13.99	26	9453	13795	34933657
Pyloric stenosis	27.67	13.99	10	9469	864	34946588
Clonal haematopoiesis	27.47	13.99	6	9473	78	34947374
Product dispensing error	26.18	13.99	18	9461	6256	34941196
Cellulitis enterococcal	25.70	13.99	6	9473	107	34947345
Foetal arrhythmia	25.64	13.99	6	9473	108	34947344
Caesarean section	24.81	13.99	12	9467	2152	34945300
Febrile neutropenia	24.26	13.99	4	9475	136845	34810607
Ischaemic hepatitis	23.60	13.99	11	9468	1817	34945635
Maternal drugs affecting foetus	23.02	13.99	14	9465	3951	34943501
Onychophagia	22.96	13.99	5	9474	64	34947388
Oligohydramnios	22.86	13.99	7	9472	361	34947091
Learning disorder	22.04	13.99	9	9470	1082	34946370
Oculogyric crisis	21.90	13.99	10	9469	1576	34945876
Tricuspid valve disease	21.81	13.99	6	9473	211	34947241
Torsade de pointes	21.74	13.99	17	9462	7192	34940260
Sepsis neonatal	20.38	13.99	6	9473	270	34947182
Ototoxicity	20.09	13.99	10	9469	1907	34945545
SAPHO syndrome	19.95	13.99	6	9473	291	34947161
Respiratory acidosis	19.92	13.99	14	9465	5036	34942416
Vasculitic rash	19.67	13.99	8	9471	951	34946501
Myasthenia gravis crisis	19.20	13.99	7	9472	620	34946832
Hepatic necrosis	18.51	13.99	12	9467	3782	34943670
Potentiating drug interaction	17.80	13.99	13	9466	4964	34942488
Pathogen resistance	17.69	13.99	17	9462	9465	34937987
Myoglobinuria	17.64	13.99	7	9472	781	34946671
Cardio-respiratory arrest neonatal	17.48	13.99	3	9476	9	34947443
Neonatal disorder	17.29	13.99	7	9472	823	34946629
Swelling face	17.29	13.99	26	9453	23079	34924373
Measles	17.01	13.99	5	9474	224	34947228
Stevens-Johnson syndrome	16.92	13.99	23	9456	18616	34928836
Foetal exposure during pregnancy	16.86	13.99	34	9445	38067	34909385
Accidental exposure to product	16.78	13.99	19	9460	12783	34934669
Hepatic failure	16.72	13.99	32	9447	34499	34912953
Exposure during pregnancy	16.64	13.99	16	9463	8918	34938534
Brain herniation	15.55	13.99	11	9468	3997	34943455
Proteus infection	15.35	13.99	7	9472	1099	34946353
Pupillary disorder	15.28	13.99	5	9474	320	34947132
Pneumonia mycoplasmal	15.26	13.99	6	9473	654	34946798
Megacolon	14.82	13.99	8	9471	1802	34945650
Visual acuity reduced	14.77	13.99	20	9459	16129	34931323
Altered state of consciousness	14.68	13.99	24	9455	22869	34924583
Malignant neoplasm progression	14.68	13.99	3	9476	88043	34859409
Skin wrinkling	14.45	13.99	5	9474	380	34947072
Mycoplasma infection	14.13	13.99	5	9474	406	34947046

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	3317.88	11.81	1767	27224	297149	79418248
International normalised ratio fluctuation	233.08	11.81	75	28916	3379	79712018
Bloody discharge	185	11.81	55	28936	1898	79713499
Lyme disease	144.48	11.81	52	28939	3298	79712099
Maternal exposure during pregnancy	101.81	11.81	180	28811	136358	79579039
Seronegative arthritis	97.50	11.81	43	28948	4649	79710748
Abortion spontaneous	95.60	11.81	82	28909	29425	79685972
Drug interaction	95.15	11.81	349	28642	414834	79300563
Product packaging issue	71.99	11.81	24	28967	1209	79714188
Toxic epidermal necrolysis	70.50	11.81	84	28907	44497	79670900
Dislocation of vertebra	65.72	11.81	39	28952	7841	79707556
Hyphaema	62.51	11.81	20	28971	884	79714513
Necrosis ischaemic	58.83	11.81	20	28971	1070	79714327
Exposure during pregnancy	51.87	11.81	114	28877	101018	79614379
Beta haemolytic streptococcal infection	49.40	11.81	21	28970	2076	79713321
Pneumonia streptococcal	47.05	11.81	22	28969	2723	79712674
Stevens-Johnson syndrome	46.47	11.81	64	28927	39102	79676295
Ototoxicity	46.31	11.81	23	28968	3251	79712146
Drug abuse	44.42	11.81	4	28987	162687	79552710
Anaphylactic reaction	43.62	11.81	95	28896	83648	79631749
Death	41.68	11.81	90	28901	566424	79148973
Drug intolerance	41.50	11.81	198	28793	263921	79451476
Wheezing	40.23	11.81	113	28878	116551	79598846
Completed suicide	39.50	11.81	20	28971	245747	79469650
Infection	37.81	11.81	181	28810	241531	79473866
Febrile neutropenia	36.82	11.81	19	28972	230980	79484417
Spinal fusion surgery	36.21	11.81	23	28968	5215	79710182
Adjustment disorder with depressed mood	35.16	11.81	28	28963	9058	79706339
Pneumococcal infection	34.41	11.81	13	28978	945	79714452
Drug tolerance decreased	33.99	11.81	32	28959	12946	79702451
Mass excision	33.36	11.81	10	28981	355	79715042
Spondylitis	33.27	11.81	21	28970	4710	79710687
Wound infection	32.76	11.81	42	28949	23949	79691448
Ulcerative keratitis	32.71	11.81	19	28972	3670	79711727
Vertigo positional	31.80	11.81	18	28973	3312	79712085
Acute generalised exanthematous pustulosis	31.46	11.81	35	28956	17219	79698178
Caesarean section	31.10	11.81	30	28961	12505	79702892
Stupor	30.56	11.81	23	28968	6849	79708548
Purpura senile	29.69	11.81	10	28981	520	79714877
Tarsal tunnel syndrome	29.58	11.81	10	28981	526	79714871
Torsade de pointes	26.67	11.81	34	28957	19278	79696119
Intraocular pressure increased	26.64	11.81	24	28967	9181	79706216
Anaemia	26.28	11.81	79	28912	444936	79270461
Rash	25.72	11.81	322	28669	578036	79137361
Breast cancer stage III	25.30	11.81	24	28967	9802	79705595
Coagulation time prolonged	25.22	11.81	14	28977	2481	79712916
Malignant neoplasm progression	25.14	11.81	9	28982	135981	79579416
Learning disorder	25.01	11.81	9	28982	570	79714827
Benign laryngeal neoplasm	24.88	11.81	5	28986	30	79715367
Therapeutic product effect incomplete	24.29	11.81	109	28882	141536	79573861
Serum sickness-like reaction	24.20	11.81	9	28982	626	79714771
Deafness bilateral	24.13	11.81	13	28978	2172	79713225
Vomiting	24.00	11.81	357	28634	665471	79049926
Oligohydramnios	23.63	11.81	15	28976	3397	79712000
Premature rupture of membranes	23.58	11.81	16	28975	4053	79711344
Live birth	22.79	11.81	31	28960	18713	79696684
Respiratory acidosis	22.65	11.81	24	28967	11176	79704221
Ergot poisoning	22.54	11.81	6	28985	137	79715260
Type 2 diabetes mellitus	22.36	11.81	58	28933	57064	79658333
Grip strength decreased	21.93	11.81	33	28958	21836	79693561
Corneal neovascularisation	21.73	11.81	6	28985	158	79715239
Premature delivery	21.55	11.81	34	28957	23433	79691964
Hypotension	21.37	11.81	85	28906	440232	79275165
Bronchial obstruction	21.27	11.81	13	28978	2755	79712642
Haemoglobin decreased	21.09	11.81	30	28961	222089	79493308
Walking aid user	20.98	11.81	22	28969	10126	79705271
Product dispensing error	20.97	11.81	25	28966	13238	79702159
Lip swelling	20.83	11.81	46	28945	40865	79674532
Oculogyric crisis	20.50	11.81	13	28978	2939	79712458
Urticaria	20.35	11.81	126	28865	185075	79530322
Eye pain	19.98	11.81	43	28948	37535	79677862
Pharyngeal oedema	19.92	11.81	27	28964	16245	79699152
Resorption bone increased	19.80	11.81	10	28981	1465	79713932
Rhabdomyolysis	18.92	11.81	81	28910	103050	79612347
Mixed liver injury	18.54	11.81	18	28973	7560	79707837
Neutropenia	18.49	11.81	49	28942	287661	79427736
Toxicity to various agents	18.23	11.81	85	28906	421455	79293942
Rheumatic fever	17.96	11.81	35	28956	28490	79686907
Abdominal rigidity	17.56	11.81	12	28979	3076	79712321
Swelling face	17.19	11.81	61	28930	71151	79644246
Monocytosis	16.91	11.81	8	28983	1016	79714381
Asthenia	16.79	11.81	113	28878	511576	79203821
SAPHO syndrome	16.17	11.81	6	28985	415	79714982
Amnesia	16.08	11.81	55	28936	63002	79652395
Tricuspid valve disease	16.02	11.81	6	28985	426	79714971
Ischaemic hepatitis	15.71	11.81	12	28979	3652	79711745
Dystonia	15.65	11.81	28	28963	21371	79694026
Fall	15.34	11.81	109	28882	487520	79227877
Amniotic cavity infection	15.34	11.81	7	28984	820	79714577
Vestibular disorder	15.06	11.81	10	28981	2445	79712952
Hyponatraemia	15.00	11.81	26	28965	177822	79537575
Pathogen resistance	14.89	11.81	22	28969	14320	79701077
Blood glucose increased	14.84	11.81	12	28979	114963	79600434
Abdominal pain upper	14.77	11.81	135	28856	223684	79491713
Prescribed overdose	14.35	11.81	38	28953	37845	79677552
Anal candidiasis	14.07	11.81	3	28988	25	79715372
Hip arthroplasty	13.68	11.81	36	28955	35720	79679677
Cardiac arrest neonatal	13.58	11.81	3	28988	30	79715367
Iron deficiency	13.53	11.81	18	28973	10636	79704761
Myoglobinuria	13.44	11.81	7	28984	1093	79714304
Myasthenia gravis crisis	13.37	11.81	7	28984	1104	79714293
Starvation ketoacidosis	13.29	11.81	4	28987	144	79715253
Maternal drugs affecting foetus	13.18	11.81	8	28983	1675	79713722
Swollen joint count increased	13.08	11.81	27	28964	22900	79692497
Disease progression	12.93	11.81	30	28961	184332	79531065
Potentiating drug interaction	12.93	11.81	16	28975	8803	79706594
Measles	12.82	11.81	5	28986	396	79715001
Corneal perforation	12.72	11.81	6	28985	757	79714640
Intentional overdose	12.54	11.81	12	28979	105948	79609449
Liver injury	12.40	11.81	47	28944	56567	79658830
Coma	12.38	11.81	11	28980	100638	79614759
Dermatitis allergic	12.34	11.81	23	28968	18107	79697290
Platelet count increased	12.33	11.81	26	28965	22380	79693017
Overdose	12.11	11.81	31	28960	184175	79531222
Confusional state	12.10	11.81	67	28924	317930	79397467
Disability	12.01	11.81	22	28969	17098	79698299
Pain	11.96	11.81	182	28809	703620	79011777
Platelet count decreased	11.87	11.81	34	28957	194630	79520767

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D10AF02	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne
ATC	D10AF52	DERMATOLOGICALS ANTI-ACNE PREPARATIONS ANTI-ACNE PREPARATIONS FOR TOPICAL USE Antiinfectives for treatment of acne
ATC	J01FA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Macrolides
ATC	S01AA17	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
FDA CS	M0028311	Macrolides
FDA PE	N0000009982	Decreased Sebaceous Gland Activity
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors
FDA EPC	N0000175877	Macrolide
FDA EPC	N0000175935	Macrolide Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Listeriosis	indication	4241002	DOID:11573
Gonorrhea	indication	15628003	DOID:7551
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Pertussis	indication	27836007
Acute gonococcal urethritis	indication	29864006
Neonatal conjunctivitis	indication	34298002	DOID:9699
Gonorrhea of rectum	indication	42746002
Pneumonia due to Mycoplasma pneumoniae	indication	46970008
Bacterial pneumonia	indication	53084003	DOID:874
Acute gonococcal endometritis	indication	65295003	DOID:7527
Acute bacterial sinusitis	indication	75498004
Syphilis	indication	76272004
Pneumococcal pharyngitis	indication	76651006
Nongonococcal urethritis	indication	84619001
Acne vulgaris	indication	88616000
Urethritis due to Chlamydia trachomatis	indication	179101003
Chlamydial conjunctivitis	indication	231861005	DOID:13800
Pneumococcal pneumonia	indication	233607000
Chlamydial pneumonia	indication	233609002
Neonatal pneumonia	indication	233619008
Erythrasma	indication	238418005	DOID:4131
Streptococcus pyogenes infection	indication	302809008
Infective otitis media	indication	312218008
Diphtheria	indication	397428000
Infection due to Staphylococcus aureus	indication	406602003
Recurrent Persistent Urethritis	indication
Preoperative Bowel Preparation	indication
Superficial Ocular Infection	indication
Prevention of Bacterial Endocarditis	indication
Chlamydia Cervicitis	indication
Rectal Chlamydia Trachomatis Infection	indication
Prevention of Neonatal Ophthalmia	indication
Pneumococcal Acute Otitis Media	indication
Legionnaires' Disease	indication
Rheumatic Fever Prevention	indication
Trachoma	off-label use	2576002	DOID:11265
Inhalational anthrax	off-label use	11389007
Actinomycotic infection	off-label use	11817007	DOID:8478
Enteric campylobacteriosis	off-label use	18081009
Lyme disease	off-label use	23502006	DOID:11729
Granuloma inguinale	off-label use	28867007	DOID:9113
Sinusitis	off-label use	36971009
Erysipelas	off-label use	44653001	DOID:11330
Blepharoconjunctivitis	off-label use	68659002	DOID:2456
Cutaneous anthrax	off-label use	84980006	DOID:7426
Ecthyma	off-label use	85791004
Gastrointestinal anthrax	off-label use	111798006	DOID:13386
Bacterial conjunctivitis	off-label use	128350005	DOID:9700
Bacterial infection of skin	off-label use	128936008
Lymphogranuloma venereum	off-label use	186946009	DOID:13819
Gastroesophageal reflux disease	off-label use	235595009	DOID:8534
Gastroparesis	off-label use	235675006
Chancroid	off-label use	266143009	DOID:13778
Meibomianitis	off-label use	309779001
Infective blepharitis	off-label use	312219000
Bacterial keratitis	off-label use	314557000
Erysipeloid	off-label use	400105005
Anthrax	off-label use	409498004	DOID:7427
Relapsing fever	off-label use	420079008	DOID:13034
Gastroscopy Adjunct	off-label use
Listeria Monocytogenes Septicemia	off-label use
Ureaplasma Pneumonia	off-label use
Torsades de pointes	contraindication	31722008
Third trimester pregnancy	contraindication	41587001
Megaloblastic anemia due to folate deficiency	contraindication	85649008	DOID:14026
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Cholestatic hepatitis	contraindication	95556007
Anemia due to enzyme deficiency	contraindication	111577008
Prolonged QT interval	contraindication	111975006
Hearing disorder	contraindication	128540005
Liver function tests abnormal	contraindication	166603001
Disease of blood AND/OR blood-forming organ	contraindication	191124002	DOID:74
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000
Erythroderma	contraindication	399992009
Porphyria	contraindication	418470004
Congenital long QT syndrome	contraindication	442917000
Inflammatory dermatosis	contraindication	703938007

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Bacterial pneumonia	Indication
Cats	Upper respiratory infections	Indication
Cats	Secondary infections associated with panleukopenia	Indication
Cats	Bacterial wound infections caused by Staphylococcus species	Indication
Cats	Bacterial wound infections caused by Streptococcus species	Indication
Cattle	Bovine respiratory disease (BRD) associated with Pasturella multiocida	Indication
Cattle	Mastitis caused by Staphylococcus aureus	Indication
Cattle	Mastitis caused by Streptococcus dysgalactiae	Indication
Cattle	Mastitis caused by Streptococcus dysgalactiae	Indication
Cattle	Mastitis caused by Streptococcus uberis	Indication
Chickens	Prevention and reduction of lesions and in lowering severity of chronic respiratory disease	Indication
Chickens	Prevention of infectious coryza	Indication
Chickens	Prevention of chronic respiratory disease during periods of stress	Indication
Chickens	Chronic respiratory disease caused by Mycoplasma gallisepticum	Indication
Chickens	Infectious coryza caused by Hemophilus gallinarum	Indication
Dogs	Bacterial pneumonia	Indication
Dogs	upper respiratory infections	Indication
Dogs	Endometritis and metritis	Indication
Dogs	Bacterial wound infections caused by Staphylococcus species	Indication
Dogs	Bacterial wound infections caused by Streptococcus species	Indication
Dogs	Bacterial wound infections caused by Corynebacterium species	Indication
Turkeys	Chronic respiratory disease during periods of stress	Indication
Turkeys	Prevention and reduction of lesions and in lowering severity of chronic respiratory disease	Indication
Turkeys	Control of blue comb (nonspecific infectious enteritis)	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Gallimycin-100P	Bimeda Animal Health Limited	1
Erythro - 100, 200, Gallimycin-100	Bimeda Animal Health Limited	1
Gallimycin PFC	Bimeda Animal Health Limited	1
Erythro-36 Dry, Gallimycin-36 Dry	Bimeda Animal Health Limited	1
Gallimycin-36 Sterile	Bimeda Animal Health Limited	1
Erythromast 36	Zoetis Inc.	1
Erythro-100 Injection	Bimeda Animal Health Limited	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.65	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN	IC50	7.41	CHEMBL
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN	IC50	4.82	WOMBAT-PK
Bile salt export pump	Transporter	O95342	ABCBB_HUMAN	IC50	5.39	CHEMBL
Motilin receptor	GPCR	O43193	MTLR_HUMAN	Ki	4.43	CHEMBL
Cytochrome P450 1B1	Enzyme	Q16678	CP1B1_HUMAN	IC50	4.40	CHEMBL

External reference:

ID	Source
4017594	VUID
N0000145975	NUI
D00140	KEGG_DRUG
23067-13-2	SECONDARY_CAS_RN
3847-29-8	SECONDARY_CAS_RN
643-22-1	SECONDARY_CAS_RN
4017591	VANDF
4017594	VANDF
4017595	VANDF
4017596	VANDF
C0014806	UMLSCUI
CHEBI:42355	CHEBI
ERY	PDB_CHEM_ID
CHEMBL2110577	ChEMBL_ID
CHEMBL532	ChEMBL_ID
CHEMBL1200506	ChEMBL_ID
CHEMBL3545060	ChEMBL_ID
CHEMBL1200510	ChEMBL_ID
D004917	MESH_DESCRIPTOR_UI
DB00199	DRUGBANK_ID
C010948	MESH_SUPPLEMENTAL_RECORD_UI
C011462	MESH_SUPPLEMENTAL_RECORD_UI
C025000	MESH_SUPPLEMENTAL_RECORD_UI
1456	IUPHAR_LIGAND_ID
39	INN_ID
63937KV33D	UNII
12560	PUBCHEM_CID
24346	RXNORM
33316	MMSL
3627	MMSL
4675	MMSL
4678	MMSL
4679	MMSL
4680	MMSL
4769	MMSL
4799	MMSL
72164	MMSL
d00046	MMSL
002755	NDDF
002758	NDDF
002759	NDDF
002760	NDDF
30427009	SNOMEDCT_US
372694001	SNOMEDCT_US
39152007	SNOMEDCT_US
698006	SNOMEDCT_US
83981000	SNOMEDCT_US
96032005	SNOMEDCT_US
96033000	SNOMEDCT_US
4501-00-2	SECONDARY_CAS_RN
7704-67-8	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5571	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5572	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
ERYGEL	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8075	GEL	20 mg	TOPICAL	NDA	18 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0378-8212	GEL	20 mg	TOPICAL	NDA authorized generic	18 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0404-7191	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6476	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6476	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6482	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6482	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	13 sections
Erythrocin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-6482	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	NDA	13 sections
erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	0574-4024	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythrocin Stearate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-594	TABLET, FILM COATED	250 mg	ORAL	ANDA	23 sections
Erythrocin Stearate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-595	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	13668-586	TABLET, DELAYED RELEASE	250 mg	ORAL	ANDA	25 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	13668-588	TABLET, DELAYED RELEASE	500 mg	ORAL	ANDA	25 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-606	TABLET, COATED	250 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-606	TABLET, COATED	250 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-606	TABLET, COATED	250 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-607	TABLET, COATED	500 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-607	TABLET, COATED	500 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13668-607	TABLET, COATED	500 mg	ORAL	ANDA	14 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	13985-605	OINTMENT	5 mg	OPHTHALMIC	ANDA	18 sections
Erythromycin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-116	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	24 sections
Erythromycin Lactobionate	HUMAN PRESCRIPTION DRUG LABEL	1	14789-116	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	24 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-088	CAPSULE, DELAYED RELEASE	250 mg	ORAL	ANDA	22 sections
ERY-TAB	HUMAN PRESCRIPTION DRUG LABEL	1	16590-089	TABLET, DELAYED RELEASE	333 mg	ORAL	ANDA	27 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-090	OINTMENT	5 mg	OPHTHALMIC	ANDA	9 sections
ERYTHROMYCIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-091	TABLET, FILM COATED	250 mg	ORAL	ANDA	17 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-070	OINTMENT	5 mg	OPHTHALMIC	ANDA	19 sections
Erythromycin	HUMAN PRESCRIPTION DRUG LABEL	1	17478-070	OINTMENT	5 mg	OPHTHALMIC	ANDA	19 sections